Herpes simplex virus in infancy: Evaluation of national surveillance case capture
Angela Berkhout,Daniel K Yeoh,Suzy Teutsch,Anne Morris,Clare Nourse,Julia E Clark,Christopher C Blyth,Cheryl A Jones,APSU Neonatal HSV Study Advisory Group,Cheryl Jones,Carlos Nunez Miranda,Dannielle Handel,Marie Deverell,Amy Phu,Christopher Blyth,Daniel Yeoh,Pamela Palasanthiran,William Rawlinson,Amanda Gwee,Matthew O'Brien,Celia Cooper,Katie Flanagan,Tom Connell,David Isaacs,Peter McIntyre,Corrado Minutillo,Tony Cunningham
DOI: https://doi.org/10.1111/jpc.16596
Abstract:Aim: As herpes simplex virus (HSV) in infancy is not a mandatory notifiable condition in Australia, completeness of ascertainment by the Australian Paediatric Surveillance Unit (APSU) has been difficult to evaluate to date. We evaluated case capture in Queensland (QLD) and Western Australia (WA) using statewide laboratory and clinical data and complementary surveillance data collected via the APSU. Methods: HSV polymerase chain reaction positive results in infants (0-3 months) from 2007 to 2017 were obtained from statewide public pathology providers in QLD and WA. Clinical data were extracted from patient records and compared to APSU reported cases. Results: A total of 94 cases of HSV disease in infancy (70 QLD; 24 WA) were identified from laboratory data sets, compared to 36 cases (26 QLD; 10 WA) reported to the APSU. In total there was 102 unique cases identified; 28 cases were common to both data sets (seven skin eye mouth (SEM) disease, 13 central nervous system (CNS) disease and eight disseminated disease). Active surveillance captured 35% (36/102) of cases overall including 74% (14/19) of CNS, 71% (10/14) of disseminated and 17% (12/69) of SEM disease cases, respectively. Surveillance reported cases had a higher case-fatality rate compared to those not reported (14% vs. 3%, P = 0.038). Neurological sequelae at discharge were comparable between the groups. Conclusion: Active surveillance captures one third of hospitalised HSV cases in QLD and WA, including the majority with severe disease. However, morbidity and mortality remain high. Future studies on HSV will rely on observational studies. Enhanced case ascertainment through combined laboratory and surveillance data is essential for better understanding and improving outcomes.